

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
WO 01/22980 A1(51) International Patent Classification?: A61K 35/78,  
A61P 1/00

(21) International Application Number: PCT/AU00/01159

(22) International Filing Date:  
25 September 2000 (25.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PQ 3050 24 September 1999 (24.09.1999) AU  
PQ 4064 16 November 1999 (16.11.1999) AU

(71) Applicant and

(72) Inventor: RUDOV, David [AU/AU]; 252 Collins Street,  
Melbourne, VIC 3000 (AU).(74) Agent: GRANT, Michael, John; Patent Attorney Ser-  
vices, 26 Ellingworth Parade, Box Hill, VIC 3128 (AU).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

WO 01/22980 A1

(54) Title: SIDE EFFECTS TREATMENT

(57) Abstract: The invention provides a novel use of a substance comprising a pharmaceutically acceptable liquid extract from a juice derived from cereal plants (which includes wild grasses) and carried in a pharmaceutically acceptable carrier or excipient for application to and take up by an animal subject. The use is for the manufacture of a product for the adjunct treatment of animals including humans, to reduce the incidence or severity of side effects associated with primary chemical treatment of the animal. The invention also provides a product for the adjunct treatment of animals, a process for the adjunct treatment of animals, an adjunct secondary treatment product effective to reduce the incidence or severity of side effects, and a process for enhancing the therapeutic treatment of an animal.